Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.

In recent years, heterologous prime-boost vaccines have been demonstrated to be an effective strategy for generating protective immunity, consisting of both humoral and cell-mediated immune responses against a variety of pathogens including HIV-1. Previous reports of preclinical and clinical studies...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rachel Buglione-Corbett, Kimberly Pouliot, Robyn Marty-Roix, Kim West, Shixia Wang, Egil Lien, Shan Lu
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/bf5671cfaace498e94e12242c040d5b4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bf5671cfaace498e94e12242c040d5b4
record_format	dspace
spelling	oai:doaj.org-article:bf5671cfaace498e94e12242c040d5b42021-11-18T08:57:06ZSerum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.1932-620310.1371/journal.pone.0074820https://doaj.org/article/bf5671cfaace498e94e12242c040d5b42013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24019983/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203In recent years, heterologous prime-boost vaccines have been demonstrated to be an effective strategy for generating protective immunity, consisting of both humoral and cell-mediated immune responses against a variety of pathogens including HIV-1. Previous reports of preclinical and clinical studies have shown the enhanced immunogenicity of viral vector or DNA vaccination followed by heterologous protein boost, compared to using either prime or boost components alone. With such approaches, the selection of an adjuvant for inclusion in the protein boost component is expected to impact the immunogenicity and safety of a vaccine. In this study, we examined in a mouse model the serum cytokine and chemokine profiles for several candidate adjuvants: QS-21, Al(OH)3, monophosphoryl lipid A (MPLA) and ISCOMATRIX™ adjuvant, in the context of a previously tested pentavalent HIV-1 Env DNA prime-protein boost formulation, DP6-001. Our data revealed that the candidate adjuvants in the context of the DP6-001 formulation are characterized by unique serum cytokine and chemokine profiles. Such information will provide valuable guidance in the selection of an adjuvant for future AIDS vaccine development, with the ultimate goal of enhancing immunogenicity while minimizing reactogenicity associated with the use of an adjuvant. More significantly, results reported here will add to the knowledge on how to include an adjuvant in the context of a heterologous prime-protein boost vaccination strategy in general.Rachel Buglione-CorbettKimberly PouliotRobyn Marty-RoixKim WestShixia WangEgil LienShan LuPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 9, p e74820 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Rachel Buglione-Corbett Kimberly Pouliot Robyn Marty-Roix Kim West Shixia Wang Egil Lien Shan Lu Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.
description	In recent years, heterologous prime-boost vaccines have been demonstrated to be an effective strategy for generating protective immunity, consisting of both humoral and cell-mediated immune responses against a variety of pathogens including HIV-1. Previous reports of preclinical and clinical studies have shown the enhanced immunogenicity of viral vector or DNA vaccination followed by heterologous protein boost, compared to using either prime or boost components alone. With such approaches, the selection of an adjuvant for inclusion in the protein boost component is expected to impact the immunogenicity and safety of a vaccine. In this study, we examined in a mouse model the serum cytokine and chemokine profiles for several candidate adjuvants: QS-21, Al(OH)3, monophosphoryl lipid A (MPLA) and ISCOMATRIX™ adjuvant, in the context of a previously tested pentavalent HIV-1 Env DNA prime-protein boost formulation, DP6-001. Our data revealed that the candidate adjuvants in the context of the DP6-001 formulation are characterized by unique serum cytokine and chemokine profiles. Such information will provide valuable guidance in the selection of an adjuvant for future AIDS vaccine development, with the ultimate goal of enhancing immunogenicity while minimizing reactogenicity associated with the use of an adjuvant. More significantly, results reported here will add to the knowledge on how to include an adjuvant in the context of a heterologous prime-protein boost vaccination strategy in general.
format	article
author	Rachel Buglione-Corbett Kimberly Pouliot Robyn Marty-Roix Kim West Shixia Wang Egil Lien Shan Lu
author_facet	Rachel Buglione-Corbett Kimberly Pouliot Robyn Marty-Roix Kim West Shixia Wang Egil Lien Shan Lu
author_sort	Rachel Buglione-Corbett
title	Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.
title_short	Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.
title_full	Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.
title_fullStr	Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.
title_full_unstemmed	Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.
title_sort	serum cytokine profiles associated with specific adjuvants used in a dna prime-protein boost vaccination strategy.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/bf5671cfaace498e94e12242c040d5b4
work_keys_str_mv	AT rachelbuglionecorbett serumcytokineprofilesassociatedwithspecificadjuvantsusedinadnaprimeproteinboostvaccinationstrategy AT kimberlypouliot serumcytokineprofilesassociatedwithspecificadjuvantsusedinadnaprimeproteinboostvaccinationstrategy AT robynmartyroix serumcytokineprofilesassociatedwithspecificadjuvantsusedinadnaprimeproteinboostvaccinationstrategy AT kimwest serumcytokineprofilesassociatedwithspecificadjuvantsusedinadnaprimeproteinboostvaccinationstrategy AT shixiawang serumcytokineprofilesassociatedwithspecificadjuvantsusedinadnaprimeproteinboostvaccinationstrategy AT egillien serumcytokineprofilesassociatedwithspecificadjuvantsusedinadnaprimeproteinboostvaccinationstrategy AT shanlu serumcytokineprofilesassociatedwithspecificadjuvantsusedinadnaprimeproteinboostvaccinationstrategy
_version_	1718421107851132928

Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.

Ejemplares similares